PharmaCyte (NASDAQ: PMCB) takes a reverse stock split to regain Nasdaq compliance

by · The Markets Daily

What happened

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) put a 1-for-19 reverse split of its common stock into effect on Nov. 12. The company says the split should lift the share price so it can regain compliance with the minimum bid price rule for The Nasdaq Capital Market.

Shares outstanding fall from approximately 10,755,649 as of Nov. 11 to approximately 566,087. Split-adjusted trading began at the open on Nov. 13 under the same PMCB ticker, with a new identifier for the stock.

Stockholders approved a reverse split at the March 30 annual meeting. They let the board pick a ratio between 1-for-1.1 and 1-for-100. PharmaCyte filed a certificate of amendment with the Nevada Secretary of State on Nov. 10 to set the ratio at 1-for-19.

Options, warrants and convertible securities were adjusted in proportion. Holders who would receive a fractional share get cash based on the Nov. 12 closing price, adjusted for the split. Book-entry holders need take no action.

Key numbers

MetricLatestChangeSource
Reverse split ratio1-for-19SEC 8-K
Shares outstanding before split (as of Nov. 11, 2026)approximately 10,755,649SEC 8-K press release (Exhibit 99.1)
Shares outstanding after splitapproximately 566,087SEC 8-K press release (Exhibit 99.1)
Ratio range stockholders authorized1-for-1.1 to 1-for-100SEC 8-K

Read more: PharmaCyte Biotech (PMCB) company research

Why it matters

For holders, the split changes the share count and the price per share. It does not change what the company owns or owes. Apart from fractional shares paid in cash, each holder keeps the same stake.

The total authorized share count was not reduced. The gap between shares authorized and shares outstanding is now much wider.

OptimistFi has argued that PharmaCyte's equity value is binary. It turns on whether the company revives or licenses its clinical assets and monetizes its securities holdings, or becomes a cash-constrained shell. The split addresses the listing rule and leaves that question where it was.

A reverse split rearranges the share count. It does not by itself add cash, improve operations or secure the Nasdaq listing.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Split-adjusted trading began Nov. 13, so the share price on The Nasdaq Capital Market is the first test. A price that stays above the minimum bid requirement would support regaining compliance. A slide back below it would weaken the case.

Holders of physical stock certificates will get exchange instructions from the transfer agent, Equiniti Trust Company, LLC.

More from OptimistFi

From OptimistFi Perps

Sources

Explore OptimistFi research on PharmaCyte Biotech, Inc.: https://optimistfi.com/stocks/PMCB

Browse PharmaCyte Biotech, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the PharmaCyte Biotech, Inc. company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.